Follow Us Here:

Cancer Knowledge Network

Cancer Knowledge Network and Current Oncology are proudly published by Multimed Inc.
0
Menu
Advocate - Educate - Innovate

Working During Chemotherapy

workingduringchemo

by Kristine Nally, B.S., Microbiology

Whether or not to continue working can be an important concern for individuals preparing for chemotherapy.  However, there is very little published research regarding work patterns, factors that affect the decision to work and support from employers during active cancer treatment.  The decision and indeed the ability to continue working is highly individual and may be affected by physical and mental health, type and stage of cancer, age, type of work and finances.

For many people, working is an integral part of feeling “normal” and can have a positive psychological impact during a difficult time.  In addition, the increased length of cancer treatments means that some people will need to work for financial reasons.  Luckily, there have been great advances in the treatment of chemotherapy related side effects and some people that want to work, find that they can.

Continue reading

Factors related to the implementation and use of an innovation in cancer surgery

A Resident Education Article

Click here to read the full article:

Current Oncology, Volume 18, No. 6

by Robin Urquhart, MSc, Cancer Outcomes Research Program, Cancer Care Nova Scotia, Halifax, NS.

Across Canada, synoptic reporting tools are increasingly being implemented into clinical practice, in specialties such as radiology, endoscopy, surgery, and pathology. Synoptic reports capture data items in a structured, standardized format and contain information critical for understanding a disease, the technical details of a procedure, and the subsequent impacts on patient care. Most synoptic reporting tools are now electronic, with data entered on a computer screen via drop-down menus, check boxes, and radial buttons. For many of these reports, all of the details considered essential to the procedure are often mandatory, which means the clinician cannot complete the report and sign-off without entering the required information.

Continue reading

Invasive mediastinal staging of non-small-cell lung cancer: a clinical practice guideline

by G.E. Darling, A.J. Dickie, R.A. Malthaner, E.B. Kennedy, R. Tey

 

Abstract

Introduction

In non-small-cell lung cancer (nsclc), invasive mediastinal staging is typically used to guide treatment decision-making. Here, we present clinical practice guideline recommendations for invasive mediastinal staging in nsclc patients who have been staged T1–4, N0–3, with no distant metastases.

Continue reading

The cost–utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer

by T. Younis, D. Rayson, C. Skedgel

Abstract

Purpose

The adoption of a chemotherapeutic regimen in oncologic practice is a function of both its clinical and its economic impacts on cancer management. For breast cancer, U.S. Oncology trial 9735 reported significant improvements in disease-free and overall survival favoring adjuvant tc (docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles) compared with ac (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles). We carried out an economic evaluation to examine the cost–utility of adjuvant tc relative to ac, in terms of cost per quality-adjusted life year (qaly) gained, given the improved breast cancer outcomes and higher costs associated with the tc regimen.

Continue reading

Patterns of Presentation, Referral, and Treatment of Hepatocellular Carcinoma in a Pre-Sorafenib Era: Experience of a Canadian Provincial Cancer Agency

by T. Sundaralingam, S. Gill

Abstract

Background

Systemic treatment options in hepatocellular carcinoma (hcc) are limited. Sorafenib, a multikinase inhibitor, has been shown to improve survival in patients with advanced hcc and adequate hepatic reserve. Currently, the proportion of referred patients with hcc that would be eligible for sorafenib therapy is unclear. We reviewed patterns in the presentation and management of referred patients with hcc at the BC Cancer Agency (bcca) before the availability of sorafenib.

Continue reading

Inter-rater reliability between musculoskeletal radiologists and orthopedic surgeons on computed tomography imaging features of spinal metastases

by L. Khan, G. Mitera, L. Probyn, M. Ford, M. Christakis, J. Finkelstein, A. Donovan, L. Zhang, L. Zeng, J. Rubenstein, A. Yee, L. Holden, E. Chow

Abstract

Introduction

The primary objective of this pilot study was to examine the inter-rater reliability in scoring the computed tomography (ct) imaging features of spinal metastases in patients referred for radiotherapy (rt) for bone pain.

Continue reading

Page 135 of 148« First...10...134135136137...140...Last »